Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 20, 2008, Pages 7269-7274

  Jazdzewski, Krystian ^a   Murray, Elizabeth L ^b   Franssila, Kaarle ^c   Jarzab, Barbara ^d   Schoenberg, Daniel R ^b   De La Chapelle, Albert ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Genetic predisposition; microRNA processing; miR 146; Polymorphism; Thyroid cancer

Indexed keywords

INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; MICRORNA; MICRORNA 146A; PROTEIN PATCHED 1; PROTEIN RET; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6;

ALLELE; ARTICLE; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENE TARGETING; GENETIC POLYMORPHISM; GENOTYPE; GERM LINE; HETEROZYGOSITY; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; THYROID PAPILLARY CARCINOMA;

ALLELES; CARCINOMA; CASE-CONTROL STUDIES; CELL LINE, TUMOR; COHORT STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MICRORNAS; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; THYROID NEOPLASMS; TRANSFECTION;

EID: 44449153200     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0802682105     Document Type: Article

References (30)

1. Jemal A, et al. (2007) Cancer statistics 2007. CA Cancer J Clin 57:43-66.
2. Grieco M, et al. (1990) PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 60:557-563.
3. Bongarzone I, et al. (1994) Frequent activation of ret protooncogene by fusion with a new activating gene in papillary thyroid carcinomas. Cancer Res 54:2979-2985.
4. Cohen Y, et al. (2003) BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 95:625-627.
5. Fukushima T, et al. (2003) BRAF mutations in papillary carcinomas of the thyroid. Oncogene 22:6455-6457.
6. Kimura ET, et al. (2003) High prevalence of BRAF mutations in thyroid cancer: Genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63:1454-1457.
7. Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH (1994) Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst 86:1600-1608.
8. Czene K, Lichtenstein P, Hemminki K (2002) Environmental and heritable causes of cancer among 9.6 million individuals in the Swedish Family-Cancer Database. Int J Cancer 99:260-266.
9. Canzian F, et al. (1998) A gene predisposing to familial thyroid tumors with cell oxyphilia maps to chromosome 19p13.2. Am J Hum Genet 63:1743-1748.
10. McKay JD, et al. (2001) Localization of a susceptibility gene for familial non-medullary thyroid carcinoma to chromosome 2q21. Am J Hum Genet 69: 440- 446.
11. Bartel DP (2004) MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116:281-297.
12. Croce CM, Calin GA (2005) miRNAs, cancer, and stem cell division. Cell 122:6-7.
13. Esquela-Kerscher A, Slack FJ (2006) Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 6:259-269.
14. Zhang B, et al. (2007) microRNAs as oncogenes and tumor suppressors. Dev Biol 302:1-12.
15. Lu J, et al. (2005) MicroRNA expression profiles classify human cancers. Nature 435:834-838.
16. Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6:857-866.
17. He H, et al. (2005) The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci USA 102:19075-19080.
18. Pallante P, et al. (2006) MicroRNA deregulation in human thyroid papillary carcinomas. Endocr Relat Cancer 13:497-508.
19. Taganov KD, Boldin MP, Chang K-J, Baltimore D (2006) NF-kB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA 103:12481-12486.
20. Rehmsmeier M, Steffen P, Hochsmann M, Giegerich R (2004) Fast and effective prediction of microRNA/target duplexes. RNA 10:1507-1517.
21. Gottwein E, Cai X, Cullen BR (2006) A novel assay for viral microRNA function identifies a single nucleotide polymorphism that affects Drosha processing. J Virol 80:5321-5326.
22. Duan R, Pak C, Jin P (2007) Single nucleotide polymorphism associated with mature miR-125a alters the processing of pri-miRNA. Hum Mol Genet 6:1124-1131.
23. Lee Y, Jeon K, Lee J-T, Kim S, Kim VN (2002) MicroRNA maturation: Stepwise processing and subcellular localization. EMBO J 21:4663-4670.
24. Taganov KD, Boldin MP, Baltimore D (2007) MicroRNAs and immunity: Tiny players in a big field. Immunity 26:133-137.
25. Cameron JE, et al. (2008) Epstein-Barr virus latent membrane protein 1 induces cellular microRNA miR-146a, a modulator of lymphocyte signaling pathways. J Virol 82:1946-1958.
26. Karin M, Lin A (2002) NF-kappaB at the crossroads of life and death. Nat Immunol 3:221-227.
27. Visconti R, et al. (1997) Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NFkappaB p65 protein expression. Oncogene 15:1987-1994.
28. Pacifico F, et al. (2004) Oncogenic and anti-apoptotic activity of NF-kappa B in human thyroid carcinomas. J Biol Chem 279:54610-54619.
29. McCall KD, et al. (2007) High basal levels of functional toll-like receptor 3 (TLR3) and noncanonical Wnt5a are expressed in papillary thyroid cancer and are coordinately decreased by phenylmethimazole together with cell proliferation and migration. Endocrinology 148:4226-4237.
30. Palona I, et al. (2006) BRAFV600E promotes invasiveness of thyroid cancer cells through nuclear factor kappaB activation. Endocrinology 147:5699-5707.